NCT06449352CompletedPhase 4
Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost
Effect of the Addition of Netarsudil 0.02% vs. Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005%
Source: ClinicalTrials.gov · Last updated 22 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 3 Jun 2024
- Start date
- 13 Jun 2024
- Primary completion date
- 22 Sept 2025
- Lead sponsor
- Westlake Eye Specialists
- Diseases
- Glaucoma
- NCT number
- NCT06449352
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 100
- From 13 Jun 2024 to the primary completion date, 22 Sept 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have had incisional surgery for glaucoma (eg: MIGs).
- Prior allergy to brimonidine or netarsudil, and known to have previously failed either brimonidine or netarsudil.
- Ocular surgery (e.g., cataract, laser, refractive) during the study or 1 year prior to entering the study.
- The principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial.
Other
- If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.
- Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
- Other forms of secondary glaucoma.
- Patients with abnormal anterior segment examination other than cataract will be excluded from the study.
- Patients with refractory CME or CME persisting 3 months or more.
- Children, cognitive impaired and critically ill subjects will not be enrolled.
- Central Corneal Thickness (CCT) ≤ 500.
Who the study is looking for
- Patients 18 years and older
- Diagnosed with normal tension glaucoma based on the following:
- IOP ≤ 21mmHg
- Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma
- Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year
- Open angles assessed by gonioscopy
- Have been on latanoprost monotherapy for at least 6 weeks
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Westlake Eye Specialists - Austin Office Coordinator of this site? Confirm its status | Austin | United States | Unknown status |
| Westlake Eye Specialists - Killeen Office Coordinator of this site? Confirm its status | Killeen | United States | Unknown status |
| Westlake Eye Specialists - Kyle Office Coordinator of this site? Confirm its status | Kyle | United States | Unknown status |
| Westlake Eye Specialists - New Braunfels Office Coordinator of this site? Confirm its status | New Braunfels | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.